Fair Value Calculator Fair Value Calculator
EN DE

2393 (2393) Fair Value & Analysis

Healthcare · Market cap HK$140M

2 2393 2393 · HK
PriceHK$0.0600
Fair ValueHK$0.0900
Upside+50.0%
Quality48/100
Watch 2393 for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range HK$0.0900 – HK$0.0900

Fair value as of: Jul 2, 2026

From 15 valuation models · updated today

Share price −14.3% over the past month.

Price vs Fair Value (12 months)

HK$0.1920 HK$0.0580 Fair Value HK$0.0900 Jun 2025 Jul 2026

12‑month range HK$0.0580 – HK$0.1920 · the HK$0.0600 price screens below the HK$0.0900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2393 (2393) currently trades at HK$0.0600, while our model-based Fair Value estimate is HK$0.0900 — implying the stock looks roughly 50.0% undervalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2393 generated revenue of HK$1.5B at a net margin of -5.0%. Revenue declined 39.5% year over year. It earns a return on equity of -15.1%. The balance sheet holds a net cash position of HK$23.5M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.5B
Revenue growth (YoY) -39.5%
Net margin -5.0%
Return on equity -15.1%
Free cash flow HK$289M FY2025
Operating margin -3.5%
More key figures
EPS growth (YoY) -99.5%
Net cash HK$23.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2393 reported revenue of HK$1.5B in FY2025 versus HK$4.9B in FY2021, a compound −25.9%/yr. Reported net income was −HK$75.0M in FY2025.

Revenue −25.9%/yr
FY21 HK$4.9B
FY22 HK$2.8B
FY23 HK$2.9B
FY24 HK$2.4B
FY25 HK$1.5B
Net income
FY21 HK$3.3M
FY22 −HK$992M
FY23 −HK$13.9M
FY24 HK$922M
FY25 −HK$75.0M

Is 2393 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
ABT ABT 1,600 MXN 1,228 MXN -23%
Abbott Laboratories, ABTT34 R$38.22 R$30.39 -20%
Stryker Corporation S1YK34 R$79.21 R$43.74 -45%
Medtronic plc MDT $80.25 $74.40 -7%
Boston Scientific Corporation B1SX34 R$248.75 R$221.81 -11%
Edwards Lifesciences Corporation EW $85.88 $41.02 -52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2393 (2393) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0900 versus a price of HK$0.0600 — about +50% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 2393?
Our model-based fair value for 2393 is HK$0.0900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0600.
What is the quality score of 2393?
2393 has a Quality Score of 48/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2393 (2393)?
2393 reported trailing-twelve-month revenue of about HK$1.5B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2393?
The net profit margin of 2393 is about -5.0%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.